title: Public acceptance of peramivir during the 2009 H1N1 influenza pandemic: implications for other drugs or vaccines under emergency use authorizations.
abstract: OBJECTIVE
  The Centers for Disease Control and Prevention estimated that up to 88 million H1N1 influenza cases, 398,000 hospitalizations, and up to 18,050 related deaths, including significant racial and ethnic disparities, occurred between April 2009 and March 13, 2010. The Food and Drug Administration (FDA) approved emergency use authorizations (EUAs), which allowed the distribution of unapproved drugs or the off-label use of approved drugs. In late 2009, peramivir was granted an EUA for patients with severe disease. This study examined factors associated with willingness to take peramivir.
  
  
  METHODS
  In 2010 we conducted a nationally representative survey with 2079 respondents randomly drawn from the Knowledge Networks research panel. Our completion rate was 56%. Respondents received information about peramivir from a fact sheet and then answered questions about their willingness to take the drug.
  
  
  RESULTS
  Overall, 48% of participants indicated that they would probably or definitely take peramivir. Seventy-nine percent definitely would take the drug if their doctor recommended it and there were no alternative treatments. There were significant racial differences in willingness. The term experimental to refer to the drug decreased willingness to accept peramivir among both whites and blacks.
  
  
  CONCLUSIONS
  Trust in the FDA was important for peramivir acceptance. Particular care must be taken to ensure that patients and their families understand the complex nature of EUA drugs. Lessons learned can inform communication about future EUAs. (Disaster Med Public Health Preparedness. 2015;9:166-174).
authors.affiliation: 1Department of Family Science,School of Public Health,University of Maryland,College Park,Maryland.
authors.forename: Sandra Crouse
authors.initials: SC
authors.lastname: Quinn
authors.affiliation: 2School of Public Health,University of Georgia,Athens,Georgia.
authors.forename: Karen
authors.initials: K
authors.lastname: Hilyard
authors.affiliation: 3Department of Politics and International Relations,University of Southampton,Southampton,United Kingdom.
authors.forename: Nestor
authors.initials: N
authors.lastname: Castaneda-Angarita
authors.affiliation: 4Southern Center for Communication,Health, and Poverty,University of Georgia,Athens,Georgia.
authors.forename: Vicki S
authors.initials: VS
authors.lastname: Freimuth
mesh_terms: D000146:Acids, Carbocyclic; D003517:Cyclopentanes / Q000627:therapeutic use*; D004638:Emergency Treatment / Q000523:psychology* / Q000706:statistics & numerical data; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000517:prevention & control; D010342:Patient Acceptance of Health Care; D011795:Surveys and Questionnaires
chemical_list: D000146:Acids, Carbocyclic; D003517:Cyclopentanes; D006146:Guanidines; C414210:peramivir
keywords: vaccines